JPS63303909A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPS63303909A JPS63303909A JP62140658A JP14065887A JPS63303909A JP S63303909 A JPS63303909 A JP S63303909A JP 62140658 A JP62140658 A JP 62140658A JP 14065887 A JP14065887 A JP 14065887A JP S63303909 A JPS63303909 A JP S63303909A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- external preparation
- polygonum
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 abstract description 10
- 239000002674 ointment Substances 0.000 abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 239000006210 lotion Substances 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 4
- 244000233952 Polygonum bistorta Species 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- -1 pack Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 206010042496 Sunburn Diseases 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 244000228295 Polygonum viviparum Species 0.000 abstract description 2
- 235000012804 Polygonum viviparum Nutrition 0.000 abstract description 2
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 235000014258 Polygonum bistorta Nutrition 0.000 abstract 3
- 206010040849 Skin fissures Diseases 0.000 abstract 2
- 241000227465 Bistorta tenuicaulis Species 0.000 abstract 1
- 206010004966 Bite Diseases 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 abstract 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000205407 Polygonum Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000920652 Quercus lusitanica Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、新規な皮膚外用剤に関し、さらに詳しくは、
イブキトラノオ抽出物を含有することを特徴とする皮膚
外用剤に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a novel external skin preparation, and more specifically,
The present invention relates to a skin preparation for external use, which is characterized by containing an extract of Ibuchiranium.
本発明の目的とするところは、日焼け・肌荒れ・外傷・
にきび等による皮膚の炎症を防止・緩和する、肌荒れ防
止効果、肌荒れ改善効果に優れた皮膚外用剤に関する。The purpose of the present invention is to prevent sunburn, rough skin, trauma,
This invention relates to a skin preparation for external use that prevents and alleviates skin inflammation caused by acne, etc., and has excellent effects on preventing and improving rough skin.
［従来の技術］
従来、抗炎症作用を有する植物抽出物として、甘草、黄
柏、紫根等の種々のものが知られており、肌荒れ防止、
肌荒れ改善効果を期待して、これらを皮膚外用剤に配合
する試みがなされてきた。[Prior Art] Various plant extracts such as licorice root, yellow oak, and purple root have been known as plant extracts that have anti-inflammatory effects.
Attempts have been made to incorporate these into external skin preparations in the hope of improving rough skin.
［発明が解決しようとする問題点］
しかしながら、従来使用されてきた植物抽出物では、有
効な肌荒れ改善効果を有するものは限られていた。[Problems to be Solved by the Invention] However, among the plant extracts that have been used conventionally, there are only a limited number of plant extracts that have an effective effect on improving rough skin.
［問題点を解決するための手段］
本発明者等は、係る点に鑑み、種々の植物抽出物につい
て鋭意研究した結果、イブキトラノオ抽出物が優れた抗
炎症作用を有し、かつこれを含有する皮膚外用剤におい
ても顕著な肌荒れ防止効果が得られることを見出し、本
発明を完成させたのである。[Means for Solving the Problems] In view of the above points, the present inventors conducted intensive research on various plant extracts, and found that the Ibuchiranium extract has an excellent anti-inflammatory effect and contains the same. The present invention was completed based on the discovery that a remarkable effect on preventing rough skin can be obtained even in a skin preparation for external use.
すなわち本発明は、イブキトラノオ抽出物を含有するこ
とを特徴とし、肌荒れ防止効果、肌荒れ改善効果に優れ
た皮膚外用剤を提供するものである。That is, the present invention provides a skin preparation for external use, which is characterized by containing an extract of Ibuchirania and has excellent effects on preventing and improving rough skin.
本発明において必須に使用されるイブキトラノオ抽出物
としては、イブキトラノオ（Ｐｏｌｙ−ｇｏｎｕｍ
ｂｉｓｔｏｒｔａ Ｌ、）の根茎・全草、及び一般に知
られている挙参等から抽出して得られるものであれば本
発明にとって好適に使用し得る。The Polygonum extract that is essentially used in the present invention includes Polygonum polygonum.
Any extract obtained from the rhizomes and whole plants of P. bistorta L.) and commonly known ginseng etc. can be suitably used in the present invention.
またこの他、イブキトラノオの同属植物であるムカゴト
ラノオ（Ｐｏｌｙｇｏｎｕｍ ｖｉｖｉｐａｒｕｍ Ｌ
、）、ハルトラノオ（Ｐ、ｔｅｎｕｉｃａｕｌｅ ＢＩ
ＳＳ、 ｅｔ ＭＯＯＲＥ）等も利用できる。抽出方法
は特に限定しないが、例えば抽出溶媒として、水、メチ
ルアルコール・エチルアルコール等の低級−価アルコー
ル、プロピレングリコール・１．３−ブチレンゲリコー
ル等の液状多価アルコール、酢酸エチルエステル等の低
級アルキルエステル、ベンゼン・ヘキサン等の炭化水素
、エチルエーテル等が挙げられ、これらの一種、または
二種以上を組み合わせて使用し得る。これらの抽出溶媒
と共に室温又は加温して抽出し、枦通して得られる抽出
液、またはこれを濃縮したものが用いられる。In addition, Polygonum viviparum L is a congener of Ibukitranoo.
, ), P. tenicaule BI
SS, et MOORE) etc. can also be used. The extraction method is not particularly limited, but for example, as an extraction solvent, water, lower alcohols such as methyl alcohol and ethyl alcohol, liquid polyhydric alcohols such as propylene glycol and 1,3-butylene gellicol, and lower alcohols such as ethyl acetate are used. Examples include alkyl esters, hydrocarbons such as benzene and hexane, and ethyl ether, and one type or a combination of two or more of these may be used. The extract obtained by extracting with these extraction solvents at room temperature or with heating and straining, or the concentrated version thereof is used.
皮膚外用剤中におけるイブキトラノオ抽出物の含有量は
、少なすぎる場合は効果がなく、固形分として０．００
１〜１Ｏ００重量％の範囲が本発明の目的の為には十分
であり、また製品配合上からは抽出液として ０．０１
〜２０．０重量％の範囲であれば好ましく、特に固形分
として０．Ｏ２Ｎ２．０重量％、抽出液として０．１〜
１０．０重量％の範囲であればより好ましい。If the content of Ibuchiranou extract in the skin external preparation is too low, it will not be effective, and the solid content will be 0.00.
A range of 1 to 1000% by weight is sufficient for the purpose of the present invention, and from the viewpoint of product formulation, 0.01% by weight as an extract.
It is preferable if it is in the range of ~20.0% by weight, particularly 0.0% as a solid content. O2N 2.0% by weight, 0.1~ as extract liquid
A range of 10.0% by weight is more preferable.
本発明において上記イブキトラノオ抽出物を配合する皮
膚外用基材としては、通常化粧品・医薬部外品・医薬品
に用いられる水性成分、粉末、界面活性剤、油分、保湿
剤、アルコール類、ｐＨ調整剤、防腐剤、酸化防止剤、
増粘剤、色素、香料等を必要に応じて適宜配合して調製
されたものであれば良い。In the present invention, the base material for external use on the skin in which the above-mentioned Ibuchiranium extract is blended includes aqueous ingredients, powders, surfactants, oils, humectants, alcohols, and pH adjusters that are usually used in cosmetics, quasi-drugs, and pharmaceuticals. , preservatives, antioxidants,
Any product may be used as long as it is prepared by appropriately blending thickeners, pigments, fragrances, etc. as necessary.
本発明でいう皮膚外用剤の剤型は特に限定されず、化粧
水、乳液、クリーム、パック、軟膏、分散液等の剤型と
することができる。The dosage form of the skin external preparation as referred to in the present invention is not particularly limited, and may be in the form of a lotion, emulsion, cream, pack, ointment, dispersion, or the like.
また、本発明の皮膚外用剤には、イブキトラノオ抽出物
の外、公知の薬剤、例えば、グリチルレチン酸及びその
誘導体、インドメタシン等の抗炎症剤、アスコルビン酸
、グルタチオン及びこれらの誘導体、ブチセンタエキス
、当帰エキス、全白皮エキス等の美白効果を有する薬剤
、紫外線吸収剤等を組み合わせて配合することも可能で
あり、相乗効果を期待して製品に併用しても差し支えな
い。The skin external preparation of the present invention may also contain, in addition to the Ibuchitorana extract, known drugs such as glycyrrhetinic acid and its derivatives, anti-inflammatory agents such as indomethacin, ascorbic acid, glutathione and their derivatives, butycenta extract, It is also possible to combine agents with whitening effects such as Toki extract and whole white skin extract, ultraviolet absorbers, etc., and there is no problem in using them in combination in products with the expectation of a synergistic effect.
次に本発明に係るイブキトラノオ抽出物の抗炎症作用を
示すために次の試験を行なった。Next, the following test was conducted in order to demonstrate the anti-inflammatory effect of the Ibuchitorana extract according to the present invention.
（炎症抑制試験）
カラゲニン足氾浮腫法に準じ、生後５週令のウィスター
系雄性ラットを１群１０匹とし、起炎物質として１％カ
ラゲニン生理食塩水溶液をラット後肢足匿に皮下注射し
て浮腫を生じさせた。(Inflammation suppression test) According to the carrageenan paw flood edema method, a group of 10 male Wistar rats aged 5 weeks old was subcutaneously injected with a 1% carrageenan saline solution as an inflammatory substance into the hind paws of the rats to induce edema. caused.
試料塗布群には、カラゲニン注射２時間前、１時間前及
び注射直後に、イブキトラノオ根茎メチルアルコール抽
出物を最終的に固形分として５％の割合でオリーブ油に
溶解したものを０．１ｍｌずつ塗布し、対照群にはオリ
ーブ油のみを塗布した。カラゲニン注射３時間後の浮腫
容積及び浮腫生成の抑制率を表１に示す。尚、表中の値
は各群における平均値である。To the sample-applied group, 0.1 ml of a final solid content of 5% solid content of the methyl alcohol extract of Ibuchiranium rhizome dissolved in olive oil was applied 2 hours before, 1 hour before, and immediately after the carrageenin injection. However, only olive oil was applied to the control group. Table 1 shows the edema volume and the inhibition rate of edema formation 3 hours after carrageenin injection. Note that the values in the table are average values for each group.
表 １
表１の結果から明らかな如く、本発明に係るイブキトラ
ノオ抽出物は、カラゲニンにより惹起された炎症を抑制
することが認められた。Table 1 As is clear from the results in Table 1, it was found that the Ibuchirania extract according to the present invention suppressed inflammation caused by carrageenan.
［実施例］
次に、本発明について、実施例を挙げてさらに説明する
。これらは本発明を何ら限定するものではない。[Example] Next, the present invention will be further explained by giving examples. These do not limit the present invention in any way.
実施例 ［１］ クリーム
（処方） （重量％）（１）
イブキトラノオ全草エーテル ３．０抽出物（
固形分として）
（匂 ステアリン酸 １．０（３）
ステアリルアルコール ４．０（４）モノス
テアリン酸グリセリン ３．０（５）硬化油
７．０（（へ）流動パラフィン
ｌ０８０（７） サフラワーオイル
２．０（８） ソルビタンセスキオレ
エート １．０（９） 香料
０．１（１０） カルボキシビニルポリ
マー ０．１（ロ）水酸化ナトリウム
０．０５（＋２）防腐剤
０．１（＋３） Ｍ製水
残量（製法）
Ａ （１）〜（匂を加熱溶解する。Example [1] Cream (prescription) (weight%) (1)
Ibukitranoo whole plant ether 3.0 extract (
(as solid content) (Odor Stearic acid 1.0 (3)
Stearyl alcohol 4.0 (4) Glyceryl monostearate 3.0 (5) Hydrogenated oil
7.0 ((to) Liquid paraffin
l080(7) Safflower oil
2.0 (8) Sorbitan Sesquioleate 1.0 (9) Flavoring
0.1(10) Carboxyvinyl polymer 0.1(b) Sodium hydroxide
0.05 (+2) preservative
0.1 (+3) M Seisui
Remaining amount (manufacturing method) A (1) - (Dissolve the odor by heating.
Ｂ ６０）〜（＋３）を加熱溶解する。B 60) to (+3) are heated and dissolved.
ＣＡにＢを加えて乳化をし、冷却してクリームを得る。Add B to CA to emulsify and cool to obtain cream.
実施例 ［２］ 軟膏
（処方） （重量％）（１）
イブキトラノオ根茎５０％１．３− １．０ブ
チレングリコール抽出液
（り カルボキシビニルポリマー １．０（３）
ヒドロキシエチルセルロース １．０（４）
ポリエチレングリコール １０．０（均 エチ
ルアルコール ３０．０（６） ジイ
ソプロピルアジベート ２．０（７） ジイソプ
ロパツールアミン １．１（８）精製水
残 量（製法）
Ａ（８）の一部に（匂、（３）を膨拐させる。Example [2] Ointment (prescription) (weight%) (1)
50% 1.3-1.0 Butylene Glycol Extract (Carboxyvinyl Polymer 1.0 (3)
Hydroxyethyl cellulose 1.0 (4)
Polyethylene glycol 10.0 (average) Ethyl alcohol 30.0 (6) Diisopropyl adibate 2.0 (7) Diisopropanolamine 1.1 (8) Purified water
Remaining amount (manufacturing method) A part of A (8) is expanded with (3).
Ｂ （１）、（４）〜（６）をＡに添加、攪拌する。B Add (1), (4) to (6) to A and stir.
Ｃ（８）の一部に（７）を溶解してＢに添加する。Dissolve (7) in a portion of C(8) and add to B.
ＤＣに残量の水を加え、均一に攪拌して軟膏を得る。Add the remaining amount of water to the DC and stir evenly to obtain an ointment.
比較例［１］ 軟膏 実施例［２］の処方中、（１）を除いて軟膏とする。Comparative example [1] Ointment In the formulation of Example [2], except for (1), the ointment was prepared.
上記の如くして得られた実施例［２１、比較例［２１の
軟膏を用いて、前記のカラゲニン足迦浮腫法による炎症
抑制試験を同様にして行なつた。尚、試料は各軟膏０．
１ｇずつ３回塗布した。結果は表２に示す。Using the ointments of Example [21] and Comparative Example [21] obtained as described above, an inflammation suppression test using the carrageenan foot edema method was conducted in the same manner. In addition, the samples were 0.00% of each ointment.
1 g each was applied three times. The results are shown in Table 2.
表 ２
表２の結果から明らかな如く、実施例［２］の軟膏は皮
膚の炎症を抑制する効果を有していた。また、実際に使
用したところ、実施例［２］の軟膏は、優れた肌荒れ改
善効果を有するものであった。Table 2 As is clear from the results in Table 2, the ointment of Example [2] had the effect of suppressing skin inflammation. Furthermore, when actually used, the ointment of Example [2] had an excellent effect on improving rough skin.
実施例 ［３］ 化粧水
（処方） （重量％）（１）
挙参５０％エチルアルコール ０．５抽出液
（２） エチルアルコール ７．０（
３） １，３−ブチレングリコール ７．０
（４）酢酸トコフェロール ０．０５（５
］ 防腐剤 ０．１（６）
香料 ０．０５（７
） モノオレイン酸ポリオキシ １．０エチレン
ソルビタン （２０Ｅ、Ｏ，）（８） 乳酸ナトリウ
ム ０．２（匂 セイヨウトチノキエ
キス ０．５６０） Ｍ製水
残 量（製法）
Ａ （１）〜（７）を混合溶解する。Example [3] Lotion (prescription) (weight%) (1)
50% Ethyl Alcohol 0.5 Extract (2) Ethyl Alcohol 7.0 (
3) 1,3-butylene glycol 7.0
(4) Tocopherol acetate 0.05 (5
] Preservative 0.1 (6)
Fragrance 0.05 (7
) Polyoxy monooleate 1.0 Ethylene sorbitan (20E, O,) (8) Sodium lactate 0.2 (odor: Horse chestnut extract 0.560) M Seisui
Remaining amount (manufacturing method) A Mix and dissolve (1) to (7).
Ｂ（８）〜（ＩＱ）を混合溶解する。Mix and dissolve B(8) to (IQ).
ＣＢにＡを加えて混合し、化粧水を得る。Add A to CB and mix to obtain lotion.
［発明の効果］
以上詳述した如く、本発明は、イブキトラノオ抽出物を
必須に含有することにより、その作用効果が十分発揮さ
れた新規な皮膚外用剤を提供するものである。[Effects of the Invention] As described in detail above, the present invention provides a novel skin preparation for external use, which essentially contains an extract of Ibuchiranobia, thereby fully exhibiting its effects.
すなわち、本発明により、抗炎症作用によって日焼け・
肌荒れ・外傷・にきび等に起因する皮膚の炎症に対して
有効に働く、肌荒れ防止効果に優れた皮膚外用剤の提供
が可能となったのである。In other words, the present invention provides anti-sunburn and anti-inflammatory effects.
It has now become possible to provide a skin preparation for external use that is effective against skin inflammation caused by rough skin, trauma, acne, etc. and has an excellent effect on preventing rough skin.
以 上that's all
Claims (1)
る皮膚外用剤。(1) A skin preparation for external use, characterized by containing an extract of Ibuchitoranhu extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62140658A JP2542849B2 (en) | 1987-06-04 | 1987-06-04 | Topical skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62140658A JP2542849B2 (en) | 1987-06-04 | 1987-06-04 | Topical skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63303909A true JPS63303909A (en) | 1988-12-12 |
| JP2542849B2 JP2542849B2 (en) | 1996-10-09 |
Family
ID=15273759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62140658A Expired - Lifetime JP2542849B2 (en) | 1987-06-04 | 1987-06-04 | Topical skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2542849B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| JP2007204379A (en) * | 2006-01-31 | 2007-08-16 | Ichimaru Pharcos Co Ltd | FORMULATION AND METHOD FOR ACTIVATING mTOR |
| JP2014214100A (en) * | 2013-04-24 | 2014-11-17 | 花王株式会社 | Hair growth inhibitor |
| KR20150135433A (en) * | 2013-03-27 | 2015-12-02 | 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 | Cosmetic or dermatological use of a polygonum bistorta extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60104005A (en) * | 1983-11-08 | 1985-06-08 | Kobayashi Kooc:Kk | Skin beutifying cosmetic |
-
1987
- 1987-06-04 JP JP62140658A patent/JP2542849B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60104005A (en) * | 1983-11-08 | 1985-06-08 | Kobayashi Kooc:Kk | Skin beutifying cosmetic |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| JP2007204379A (en) * | 2006-01-31 | 2007-08-16 | Ichimaru Pharcos Co Ltd | FORMULATION AND METHOD FOR ACTIVATING mTOR |
| KR20150135433A (en) * | 2013-03-27 | 2015-12-02 | 바스프 뷰티 케어 솔루션즈 프랑스 에스에이에스 | Cosmetic or dermatological use of a polygonum bistorta extract |
| JP2016515567A (en) * | 2013-03-27 | 2016-05-30 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエスＢＡＳＦ Ｂｅａｕｔｙ Ｃａｒｅ Ｓｏｌｕｔｉｏｎｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． | Cosmetic or dermatological use of Polygonum bistorta extract |
| JP2014214100A (en) * | 2013-04-24 | 2014-11-17 | 花王株式会社 | Hair growth inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2542849B2 (en) | 1996-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2969274B2 (en) | Anti-roughening agent | |
| BRPI0710096A2 (en) | compositions for hair disorders and the process for preparing such | |
| JP3407935B2 (en) | External preparation for skin | |
| JP2007269743A (en) | Skin care preparation | |
| JPH0826969A (en) | Cosmetic composition | |
| JP3800611B2 (en) | Whitening agent or pigmentation ameliorating agent | |
| JP3480952B2 (en) | External preparation for skin | |
| JP4869469B2 (en) | Melanin production promoter and gray hair improving agent | |
| JPS63303909A (en) | External preparation for skin | |
| KR102221627B1 (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| JP2501593B2 (en) | Topical agent for suppressing melanin production | |
| KR102247589B1 (en) | Cosmetic composition for improving skin comprising the moluccella laevis extraction and the hololeion maximowiczii Kitam. extraction as an effective ingredient | |
| JPH03127714A (en) | Skin cosmetic | |
| JP2602023B2 (en) | External preparation for skin | |
| JPH0643293B2 (en) | External skin preparation | |
| JP2001163764A (en) | Plant sterol wax, its producing method and preparation for external use for skin using the same | |
| JP2011046646A (en) | Antioxidant and skin external preparation | |
| JPH1179948A (en) | Hair tonic and hair cosmetic, and preparation for external use for skin for suppressing sebum secretion | |
| JP2006257059A (en) | Androgen receptor binding inhibitor, agent for hair and skin care preparation for dermal use formulated with the same | |
| JP2003012472A (en) | Hair-growing agent | |
| JP3190487B2 (en) | Anti-dandruff hair cosmetics and hair nourishes | |
| JP3826698B2 (en) | Microbial lipase inhibitor, and acne skin external preparation and dandruff skin external preparation containing the same | |
| JPH037212A (en) | Dermal preparation for external use | |
| JP2811479B2 (en) | Hair restoration | |
| JPH1046142A (en) | Antioxidant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |